ES2176199T3 - Derivados de indol como agonistas de s-ht1. - Google Patents

Derivados de indol como agonistas de s-ht1.

Info

Publication number
ES2176199T3
ES2176199T3 ES93906214T ES93906214T ES2176199T3 ES 2176199 T3 ES2176199 T3 ES 2176199T3 ES 93906214 T ES93906214 T ES 93906214T ES 93906214 T ES93906214 T ES 93906214T ES 2176199 T3 ES2176199 T3 ES 2176199T3
Authority
ES
Spain
Prior art keywords
pct
compounds
sec
agonists
nitrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93906214T
Other languages
English (en)
Inventor
John E Macor
Jolanta T Nowakowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of ES2176199T3 publication Critical patent/ES2176199T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPUESTOS DE LA FORMULA (I), DONDE A REPRESENTA UN ENLACE DIRECTO, ALQUILO DE C1 1 O 2; R1 ES HIDROGENO, ALQUILO DE C1 DE C1 Y Z SON CADA UNO INDEPENDIENTEMENTE OXIGENO, AZUFRE, NITROGENO O CARBONO, SIEMPRE QUE AL MENOS UNO DE W, X, Y Y Z SEA NITROGENO; R2, R3, R4 Y R5 SON CADA UNO INDEPENDIENTEMENTE HIDROGENO, ALQUILO DE C1 ARILO DE C1 R7, R8, UEDEN TOMARSE JUNTAMENTE PARA FORMAR UN ANILLO DE CINCO A SIETE MIEMBROS, UN ANILLO ARILO DE SEIS MIEMBROS, UN ANILLO HETEROALKILO DE CINCO A SIETE MIEMBROS, TENIENDO 1 HETEROATOMO DE N, O, O S, O UN ANILLO HETEROARILO DE CINCO A SEIS MIEMBROS, TENIENDO 1 O 2 HETEROATOMOS DE N, O, O S; R6 ES CIANO, TRIFLUOROMETILO, O ROGENO, ALQUILO DE C1 A C6 O ARILO; R7 Y R8 PUEDEN TOMARSE JUNTAMENTE PARA FORMAR UN ANILLO ALQUILO DE C4 ALKOXI; R11 ES HIDROGENO, ES 0, 1, 2 O 3; Y LOS GRUPOS ANTERIORES DE ARILO Y LAS MITADES DE ARILO DE LOS GRUPOS ANTERIORES DE ALKILARILO SE SELECCIONAN INDEPENDIENTEMENTE DE FENILO Y FENILO SUSTITUIDO, DONDE EL CITADO FENILO SUSTITUIDO PUEDE SER SUSTITUIDO POR UNO A TRES GRUPOS SELECCIONADOS DE ALQUILO DE C1 A C4, HALOGENO, HIDROXI, CIANO, CARBOXAMIDO, NITRO, Y ALCOXI DE C1 A C4, Y LAS SALES DE LOS MISMOS FARMACEUTICAMENTE ACEPTABLES. ESTOS COMPUESTOS SON UTILES EN PSICOTERAPIA Y SON AGONISTAS DE SEROTONINA POTENTES (5 EDAD, TRASTORNOS ALIMENTICIOS, OBESIDAD, ABUSO DE MEDICINAS, DOLORES DE CABEZA DE VARIAS CLASES, MIGRAÑA, HEMICRANIA O JAQUECA PAROXISMAL CRONICA Y DOLOROSA, Y DOLOR DE CABEZA ASOCIADO CON TRASTORNOS VASCULARES, Y OTROS TRASTORNOS QUE SE ORIGINAN POR LA DEFICIENTE NEUROTRANSMISION SEROTONERGICA. LOS COMPUESTOS PUEDEN TAMBIEN SER UTILES COMO ANTIHIPERTENSIVOS Y VASODILATADORES ACTUANDO CENTRALMENTE.
ES93906214T 1992-03-05 1993-03-03 Derivados de indol como agonistas de s-ht1. Expired - Lifetime ES2176199T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84664092A 1992-03-05 1992-03-05

Publications (1)

Publication Number Publication Date
ES2176199T3 true ES2176199T3 (es) 2002-12-01

Family

ID=25298499

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93906214T Expired - Lifetime ES2176199T3 (es) 1992-03-05 1993-03-03 Derivados de indol como agonistas de s-ht1.

Country Status (30)

Country Link
US (2) US5594014A (es)
EP (1) EP0629199B1 (es)
JP (1) JPH07121943B2 (es)
KR (1) KR0179073B1 (es)
CN (4) CN1032309C (es)
AT (1) ATE218566T1 (es)
AU (1) AU666716B2 (es)
BR (1) BR9306012A (es)
CA (1) CA2117643C (es)
CZ (1) CZ282652B6 (es)
DE (1) DE69331988T2 (es)
DK (1) DK0629199T3 (es)
EG (1) EG20416A (es)
ES (1) ES2176199T3 (es)
FI (1) FI930968A (es)
HU (1) HU219489B (es)
IL (1) IL104941A (es)
MX (1) MX9301197A (es)
MY (1) MY109298A (es)
NO (1) NO302617B1 (es)
NZ (1) NZ249755A (es)
PL (1) PL172388B1 (es)
PT (1) PT629199E (es)
RU (1) RU2124012C1 (es)
SK (1) SK281938B6 (es)
TW (1) TW288010B (es)
UA (1) UA39866C2 (es)
WO (1) WO1993018032A1 (es)
YU (1) YU14893A (es)
ZA (1) ZA931539B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559246A (en) * 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5607951A (en) * 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
US6380233B1 (en) 1992-04-07 2002-04-30 Pfizer Inc Indole derivatives as 5-HT1 agonists
CZ281763B6 (cs) 1992-04-07 1997-01-15 Pfizer Inc. Indolové deriváty představující 5-HT1 agonisty, způsob jejich přípravy, farmaceutické prostředky obsahující tyto látky, jejich použití a meziprodukty postupu přípravy
HUT75646A (en) * 1993-08-31 1997-05-28 Pfizer 5-arylindole derivatives and pharmaceutical compositions containing them
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
GB9420503D0 (en) * 1994-10-11 1994-11-23 Pfizer Ltd Therapeutic agents
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
NZ331104A (en) * 1995-12-29 2000-03-27 Boehringer Ingelheim Ca Ltd Phenyl thiazole derivatives that inhibit herpes replication by inhibiting the herpes helicase primase enzyme complex
US6288091B1 (en) 1995-12-29 2001-09-11 Boehringer Ingelheim Ltd. Antiherpes virus compounds and methods for their preparation and use
US5994352A (en) * 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
CN1476429A (zh) 2000-11-27 2004-02-18 �Ʒ� 治疗骨质疏松的ep4受体选择性激动剂
MXPA03009490A (es) * 2001-04-20 2004-02-12 Wyeth Corp Derivados de heterociclilalcoxi-,-alquiltio-y- alquilaminobenzazol como ligando de 5-hidroxitriptamina-6.
ITRM20020255A1 (it) * 2002-05-09 2003-11-10 Polifarma Spa Tautomero enolico dell'acido 3-indolilpiruvico, suoi sali e usi terapeutici.
ES2199086B1 (es) * 2002-07-31 2005-06-01 Cepa Schwarz Pharma Sl Nuevos derivados de cicloalcanodionas, procedimiento para su preparacion y sus aplicaciones farmacologicas.
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
AU2021215709A1 (en) * 2020-02-04 2022-09-01 Mindset Pharma Inc. 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
ZA815541B (en) * 1980-08-12 1983-03-30 Glaxo Group Ltd Heterocyclic compounds
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
IL96891A0 (en) * 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
CA2042295A1 (fr) * 1990-05-15 1991-11-16 Jacques Chauveau Derives de mediateurs endogenes, leurs sels, procede de preparation, applications, et compositions les renfermant
CA2064815C (en) * 1990-06-07 1999-11-16 Alan Duncan Robertson Therapeutic heterocyclic compounds
AU651637B2 (en) * 1990-10-15 1994-07-28 Pfizer Inc. Indole derivatives
US5208248A (en) * 1991-01-11 1993-05-04 Merck Sharpe & Dohme, Ltd. Indazole-substituted five-membered heteroaromatic compounds
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
TW263508B (es) * 1991-02-12 1995-11-21 Pfizer

Also Published As

Publication number Publication date
KR0179073B1 (ko) 1999-03-20
CN1136432A (zh) 1996-11-27
CA2117643A1 (en) 1993-09-16
MX9301197A (es) 1993-09-01
UA39866C2 (uk) 2001-07-16
US5594014A (en) 1997-01-14
EG20416A (en) 1999-02-28
PT629199E (pt) 2002-09-30
HU219489B (hu) 2001-04-28
DE69331988T2 (de) 2002-09-19
CN1044910C (zh) 1999-09-01
WO1993018032A1 (en) 1993-09-16
NO302617B1 (no) 1998-03-30
NZ249755A (en) 1996-08-27
ZA931539B (en) 1994-09-05
CN1044909C (zh) 1999-09-01
CN1082815C (zh) 2002-04-17
US5717102A (en) 1998-02-10
CN1136565A (zh) 1996-11-27
YU14893A (sh) 1996-05-20
CA2117643C (en) 2000-03-14
CN1032309C (zh) 1996-07-17
AU3733093A (en) 1993-10-05
SK105294A3 (en) 1995-05-10
IL104941A (en) 1998-06-15
PL172388B1 (pl) 1997-09-30
HU9300593D0 (en) 1993-05-28
NO943261D0 (no) 1994-09-02
NO943261L (no) 1994-09-02
ATE218566T1 (de) 2002-06-15
DE69331988D1 (de) 2002-07-11
EP0629199B1 (en) 2002-06-05
IL104941A0 (en) 1993-07-08
CN1136566A (zh) 1996-11-27
CZ212594A3 (en) 1995-06-14
BR9306012A (pt) 1997-11-18
DK0629199T3 (da) 2002-07-15
AU666716B2 (en) 1996-02-22
TW288010B (es) 1996-10-11
MY109298A (en) 1996-12-31
JPH07500353A (ja) 1995-01-12
HUT64061A (en) 1993-11-29
SK281938B6 (sk) 2001-09-11
RU2124012C1 (ru) 1998-12-27
KR950700291A (ko) 1995-01-16
RU94040914A (ru) 1996-08-10
FI930968A0 (fi) 1993-03-04
FI930968A (fi) 1993-09-06
EP0629199A1 (en) 1994-12-21
CZ282652B6 (cs) 1997-08-13
JPH07121943B2 (ja) 1995-12-25
CN1082044A (zh) 1994-02-16

Similar Documents

Publication Publication Date Title
MX9206762A (es) Derivados de indol
ES2176199T3 (es) Derivados de indol como agonistas de s-ht1.
MX9700693A (es) Derivados del 4-indol.
ES2097496T3 (es) Derivados acilaminoindol como agonistas de 5-ht1.
ES2070772A1 (es) Derivados de acilaminoindol